Brief: Sutro Biopharma Announces Update From Stro-002, Luveltamab Tazevibulin, Phase 1 Dose-Expansion Study

Sutro Biopharma

09/01/2023 22:39

Jan 9 (Reuters) - Sutro Biopharma Inc  STRO.O :
    * SUTRO BIOPHARMA ANNOUNCES UPDATE FROM STRO-002, LUVELTAMAB
TAZEVIBULIN (LUVELTA), PHASE 1 DOSE-EXPANSION STUDY AND
REGISTRATIONAL PLANS IN ADVANCED OVARIAN CANCER
    * SUTRO BIOPHARMA INC - PLANS TO INITIATE PHASE 2/3
REGISTRATION-DIRECTED STUDY CALLED REFRAME IN Q2 OF 2023
    * SUTRO BIOPHARMA INC-RESULTS FROM STRO-002 PHASE 1
DOSE-EXPANSION
STUDY DEMONSTRATE FOLRΑ-SELECTED PATIENTS EXPERIENCED MEANINGFUL
CLINICAL BENEFIT
    * SUTRO BIOPHARMA INC - SAFETY PROFILE GENERALLY CONSISTENT
WITH
PRIOR DATA WITH ASYMPTOMATIC NEUTROPENIA BEING PRIMARY ADVERSE
EVENT
    * SUTRO BIOPHARMA INC - NO NEW SAFETY SIGNALS WERE OBSERVED
IN
STUDY

Source text for Eikon:  ID:nGNX89P5K 
Further company coverage:  STRO.O 
 ((reuters.briefs@thomsonreuters.com;))